Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"

Valuation: Theralase Technologies Inc.

Market Cap 69.48M 49.01M 42.73M 39.58M 37.05M 4.62B 69.9M 470M 182M 2.28B 184M 180M 7.9B P/E 2026 *
-23.5x
P/E 2027 * 11.8x
Enterprise Value 69.48M 49.01M 42.73M 39.58M 37.05M 4.62B 69.9M 470M 182M 2.28B 184M 180M 7.9B EV / Sales 2026 *
86.6x
EV / Sales 2027 * 2.05x
Free-Float
87.46%
Yield 2026 *
-
Yield 2027 * -
1 day+2.17%
Current month+4.44%
1 month+6.82%
3 months-25.40%
6 months+51.61%
Current year+42.42%
1 week 0.23
Extreme 0.23
0.26
1 month 0.22
Extreme 0.22
0.28
Current year 0.16
Extreme 0.16
0.41
1 year 0.14
Extreme 0.145
0.41
3 years 0.14
Extreme 0.14
0.41
5 years 0.14
Extreme 0.14
0.48
10 years 0.12
Extreme 0.12
0.6
Manager TitleAgeSince
Chief Executive Officer - 2023-06-28
Director of Finance/CFO - 2019-06-26
Chief Executive Officer - 2021-11-14
Director TitleAgeSince
Chairman - -
Director/Board Member - 2019-06-26
Director/Board Member - 2007-12-31
Date Insider Type Main position Quantity % Market Cap.
05-20Buy

Director

20,900 0.0081%
05-19Sell

Chief Executive Officer

25,000 0.0097%
05-19Option

Chief Technology Officer

11,000 0.0043%
Change 5-day change 1-year change 3-year change Capi.($)
+2.17%0.00%+23.68%-16.07% 49.01M
+2.97%+3.28%+61.44%+49.91% 1.56B
+2.11%-2.16%-27.10%-38.30% 325M
+0.43%+3.07%+3.43%-49.02% 57.26M
Average +1.92%+1.31%+15.37%-13.37% 498.45M
Weighted average by Cap. +2.74%+2.35%+44.43%+31.08%

Financials

2026 *2027 *
Net sales 802K 566K 493K 457K 428K 53.38M 807K 5.42M 2.1M 26.27M 2.12M 2.08M 91.23M 33.89M 23.9M 20.84M 19.3M 18.07M 2.26B 34.09M 229M 88.75M 1.11B 89.73M 87.8M 3.85B
Net income -4.2M -2.96M -2.58M -2.39M -2.24M -280M -4.23M -28.38M -11M -138M -11.12M -10.88M -478M 6.83M 4.82M 4.2M 3.89M 3.64M 455M 6.87M 46.16M 17.89M 224M 18.09M 17.7M 777M
Net Debt - -
Logo Theralase Technologies Inc.
Theralase Technologies Inc. is a Canada-based clinical stage pharmaceutical company. The Company is engaged in the research and development of light, radiation, sound and drug-activated small molecule compounds and their associated formulations, with a primary objective of efficacy and a secondary objective of safety in the destruction of various cancers, bacteria and viruses, with minimal impact on surrounding healthy tissue. It operates through two divisions: the Drug Division and the Device Division. The Drug Division is responsible for the research and development of small molecules primarily for the treatment of cancer with assistance from the Device Division to develop medical lasers to activate them. The Device Division is responsible for the Company’s medical laser business, which researches, develops, manufactures and distributes cool laser therapy systems to healthcare practitioners, predominantly for the healing of pain.
Employees
20
Date Price Change Volume
26-06-19 0.2350 $ +2.17% 1,202
26-06-18 0.2300 $ -4.17% 182,484
26-06-17 0.2400 $ 0.00% 16,948
26-06-16 0.2400 $ +2.13% 90,302
26-06-15 0.2350 $ 0.00% 93,862
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.2350CAD
Average target price
0.7000CAD
Spread / Average Target
+197.87%

Quarterly revenue - Rate of surprise

LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!